[18F]FET PET is a useful tool for treatment evaluation and prognosis prediction of anti-angiogenic drug in an orthotopic glioblastoma mouse model

다국어 초록 (Multilingual Abstract)

O-2-18F-fluoroethyl-l-tyrosine ([18F]FET) has been widely used for glioblastomas (GBM) in clinical practice, although evaluation of its applicability in non-clinical research is still lacking. The objective of this study was to examine the value of [18F]FET for treatment evaluation and prognosis prediction of anti-angiogenic drug in an orthotopic mouse model of GBM. Human U87MG cells were implanted into nude mice and then bevacizumab, a representative anti-angiogenic drug, was administered. We monitored the effect of anti-angiogenic agents using multiple imaging modalities, including bioluminescence imaging (BLI), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET/CT). Among these imaging methods analyzed, only [18F]FET uptake showed a statistically significant decrease in the treatment group compared to the control group (P=0.02 and P=0.03 at 5 and 20 mg/kg, respectively). This indicates that [18F]FET PET is a sensitive method to monitor the response of GBM bearing mice to anti-angiogenic drug. Moreover, [18F]FET uptake was confirmed to be a significant parameter for predicting the prognosis of anti-angiogenic drug (P=0.041 and P=0.007, on Days 7 and 12, respectively, on Pearson’s correlation; P=0.048 and P=0.030, on Days 7 and 12, respectively, on Cox regression analysis). However, results of BLI or MRI were not significantly associated with survival time. In conclusion, this study suggests that [18F]FET PET imaging is a pertinent imaging modality for sensitive monitoring and accurate prediction of treatment response to anti-angiogenic agents in an orthotopic model of GBM.

참고문헌 (Reference)

1 Tobelem G, "VEGF : a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition" 2 (2): 153-164, 2007

2 Wen PY, "Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group" 28 (28): 1963-1972, 2010

3 Galldiks N, "The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy" 13 : 386-394, 2016

4 BUSCH H, "The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues" 19 (19): 1030-1039, 1959

5 Khalil AA, "The Influence of Hypoxia and pH on Bioluminescence Imaging of Luciferase-Transfected Tumor Cells and Xenografts" 2013 : 287697-, 2013

6 Eisermann K, "The Androgen Receptor and VEGF : Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer" 9 (9): 32-, 2017

7 Isselbacher KJ, "Sugar and amino acid transport by cells in culture--differences between normal and malignant cells" 286 (286): 929-933, 1972

8 Götz I, "Role of PET Imaging in Patients with High-Grade Gliomas Undergoing Anti-Angiogenic Therapy with Bevacizumab-Review of the Literature and Case Report" 4 (4): 102-108, 2014

9 Warren RS, "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis" 95 (95): 1789-1797, 1995

10 Zhang J, "Quantitative MRI assessment of glioma response to bevacizumab in a mouse model" 10 (10): 14232-14243, 2017

11 Heiland DH, "Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine" 126 (126): 567-575, 2016

12 Huang RY, "Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response" 6 : 33-, 2015

13 Vredenburgh JJ, "Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma" 13 (13): 1253-1259, 2007

14 Hutterer M, "O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma" 52 (52): 856-864, 2011

15 Jain RK, "Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy" 307 (307): 58-62, 2005

16 Gallego O, "Nonsurgical treatment of recurrent glioblastoma" 22 (22): e273-e281, 2015

17 O’Farrell AC, "Noninvasive molecular imaging for preclinical cancer therapeutic development" 169 (169): 719-735, 2013

18 Gulyás B, "New PET radiopharmaceuticals beyond FDG for brain tumor imaging" 56 (56): 173-190, 2012

19 Borgström P, "Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo" 35 (35): 1-10, 1998

20 Ramasawmy R, "Monitoring the Growth of an Orthotopic Tumour Xenograft Model: Multi-Modal Imaging Assessment with Benchtop MRI (1T), High-Field MRI (9.4T), Ultrasound and Bioluminescence" 11 (11): e0156162-, 2016

21 Holzgreve A, "Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma : SUV Measurements and Volumetric Approaches" 10 : 260-, 2016

22 Jarzabek MA, "Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary" 18 (18): 1052-1066, 2013

23 Hardee ME, "Mechanisms of glioma-associated neovascularization" 181 (181): 1126-1141, 2012

24 Mabuchi S, "Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model" 14 (14): 7781-7789, 2008

25 Jalali S, "MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy" 16 (16): 868-879, 2014

26 Jakobsen JN, "Irinotecan and bevacizumab in recurrent glioblastoma multiforme" 12 (12): 825-833, 2011

27 Krcek R, "Influence of vascular endothelial growth factor and radiation on gap junctional intercellular communication in glioblastoma multiforme cell lines" 12 (12): 1816-1822, 2017

28 Cao Y, "Future options of anti-angiogenic cancer therapy" 35 (35): 21-, 2016

29 Bagri A, "Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy" 16 (16): 3887-3900, 2010

30 Ozel O, "Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review" 2 (2): 87-94, 2016

31 Nedergaard MK, "Comparison of(18)FFET and(18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma" 43 (43): 198-205, 2016

32 Christoph S, "Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts : effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission" 6 (6): 10-, 2013

33 Fu P, "Bevacizumab treatment for newly diagnosed glioblastoma : Systematic review and meta-analysis of clinical trials" 4 (4): 833-838, 2016

34 Yanagisawa M, "Bevacizumab improves the delivery and efficacy of paclitaxel" 21 (21): 687-694, 2010

35 Friedman HS, "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma" 27 (27): 4733-4740, 2009

36 Galldiks N, "Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI" 53 (53): 1048-1057, 2012

37 Kuusk T, "Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer" 20 (20): 205-215, 2017

38 Al-Abd AM, "Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review" 8 (8): 591-605, 2017

39 Norden AD, "An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma" 92 (92): 149-155, 2009

40 Odia Y, "A phase II trial of enzastaurin(LY317615)in combination with bevacizumab in adults with recurrent malignant gliomas" 127 (127): 127-135, 2016

41 Schwarzenberg J, "3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab" 53 (53): 29-36, 2012

42 Nedergaard MK, "18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma" 10 (10): e0115315-, 2015